To hear about similar clinical trials, please enter your email below
Trial Title:
The Role of Double Pigtail Plastic Stents During Endoscopic Transmural Drainage of Pancreatic Fluid Collections.
NCT ID:
NCT06134024
Condition:
Pancreatitis, Acute
Pancreatitis, Acute Necrotizing
Pancreatic Pseudocyst
Pancreatic Necrosis
Pancreatitis, Chronic
Conditions: Official terms:
Pancreatic Pseudocyst
Pancreatitis
Pancreatitis, Acute Necrotizing
Pancreatitis, Chronic
Necrosis
Conditions: Keywords:
gastrointestinal endoscopy
transmural drainage
lams
double pigtail plastic stents
endoscopic drainage
Study type:
Interventional
Study phase:
N/A
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Procedure
Intervention name:
Introduction of double pigtail plastic stents through the LAMS during endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections
Description:
During endoscopic procedure of endoscopic transmural drainage of post-inflammatory
pancreatic and peripancreatic fluid collections the operator introduces double pigtail
plastic stents through the LAMS.
Arm group label:
LAMS with Double Pigtail Plastic Stents
Intervention type:
Procedure
Intervention name:
Endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of LAMS only
Description:
During endoscopic procedure of transmural drainage of post-inflammatory pancreatic and
peripancreatic fluid collections the operator introduces transmurally the LAMS only,
without the double pigtail plastic stents.
Arm group label:
LAMS without Double Pigtail Plastic Stents
Summary:
The goal of this clinical trial is to learn about clinical usefulness of double pigtail
plastic stents during endoscopic transmural drainage of post-inflammatory pancreatic and
peripancreatic fluid collections with use of lumen-apposing metal stents (LAMS).
The main question it aims to answer is:
Does introduction of double pigtail plastic stents through the LAMS increases efficacy
and safety of endoscopic transmural drainage of post-inflammatory pancreatic and
peripancreatic fluid collections?
Detailed description:
Acute pancreatitis (AP) of moderate-to-severe clinical course is associated with a high
risk of local complications and organ failure leading to increased mortality. Pancreatic
and peripancreatic fluid collections (PPFCs) that can appear in the late phase of
pancreatitis can take the form of pancreatic pseudocysts and walled-off pancreatic
necrosis (WOPN). These types of PPFCs are the most common local complications of acute
and chronic pancreatitis. For many years, the traditional treatment of post-inflammatory
PPFCs in the late phase of pancreatitis relied on surgical methods. However, there has
been a recent dynamic development of minimally invasive techniques, including endoscopic
transluminal methods. While endoscopic treatment is an established method of managing
these complications, some aspects of endotherapy are still a source of much controversy.
One of the most debated issues in interventional endoscopy of local complications in
pancreatitis is the use of transmural self-expanding metallic stents (SEMSs).
Endoscopic transmural drainage consists of creating a fistula between the lumen of the
PPFC and gastrointestinal tract to allow for a free outflow of fluid out of the PPFC and
into the gastrointestinal tract. During an endoscopic ultrasound (EUS)-guided procedure
of endoscopic transmural drainage of post-inflammatory PPFCs, this can be visualized in
the endosonographic image through the wall of the upper gastrointestinal tract.
Afterwards, a transmural puncture of the PPFC is performed under EUS guidance and widened
with a cystotome to a diameter of 10 Fr using coagulation. This forms a transmural
cystostomy, which joins the gastrointestinal tract and the lumen of the PPFC. The next
step of the endoscopic procedure is mechanical (with a dilator) or pneumatic (with a
high-pressure balloon) dilation of the pancreaticocystogastrostomy or
pancreaticocystoduodenostomy. Once dilated, a transmural SEMS or plastic stent(s) is
introduced through the cystostomy to facilitate free passive transmural drainage of the
collection contents into the gastrointestinal tract. Passive transmural drainage is an
effective method of endoscopic treatment of pancreatic pseudocysts, whose contents are
entirely liquid. In the case of necrotic PPFCs that contain both liquefied necrotic
material and tissue fragments, it is necessary to use active transmural drainage, which
consists of inserting an additional nasal drain through the transmural cystostomy to
enable flushing of the collection cavity in the postoperative period.
The development of advanced endoscopic techniques has led to rapid advancements in
biomedical materials, including polymers for manufacturing endoscopic devices. Currently,
there is a wide variety of transmural endoprostheses of different sizes, shapes, and
designs for endoscopic treatment of post-inflammatory PPFCs. These endoprostheses were
divided into two groups. The first group includes plastic stents, usually made of Teflon
or polyethylene. The second group is SEMSs, often referred to as "lumen-apposing metal
stents" (LAMSs), that are used in the treatment of post-inflammatory pancreatic local
complications. For many years, the only type of endoprosthesis available for use in
transmural drainage was plastic double-pigtail stents. However, LAMSs have been
attracting increasing interest as a relatively new option in endoscopy. LAMSs are a
special type of SEMS used in a variety of gastrointestinal endoscopic procedures. They
are made of nitinol wire and are fully covered with a silicone membrane.
However, the role of LAMSs in transmural drainage remains unclear. Many authors believe
that use of LAMS during endoscopic transmural drainage increases risk of complications in
form of bleeding. Despite the development of advanced endoscopic techniques and devices,
the high rates of bleeding into the PPFC lumen remain a major challenge in transmural
drainage treatment. This type of complication is often caused by blood vessels adjacent
to the fluid collection being damaged by the distal flange of the LAMS. It seems that
inserting a plastic double-pigtail stent through the LAMS limits the risk of this kind of
complication by moving the back wall of the PPFC away from the distal flange, PPFC cavity
bleeding during transmural drainage is still a major complication associated with a high
risk of fatal outcomes.
In this trial the participants with post-inflammatory PPFCs will be divided into two
arms.
The first arm will consist of participants who underwent traditional transmural drainage
procedure with use of LAMS only.
The second arm will consist of participants with PPFCs who underwent endoscopic
transmural drainage with use of LAMS and during the procedure double pigtail plastic
stents will be introduced through the LAMS in order to prevent bleeding.
Each arm will consist of at least 50 participants with post-inflammatory PPFCs.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- participants of both sexes aged above 18 years
- participants, who provided informed consent for such treatment
- eligibility for transmural endoscopic drainage of post-inflammatory pancreatic and
peripancreatic fluid collections procedure according to current medical knowledge
based on evidence-based medicine.
Exclusion Criteria:
- pregnancy, breastfeeding, or intention to become pregnant during the study
- contraindications to electrosurgical instruments
- allergy to any of the materials used in the study
- participants ineligible for endoscopic treatment
- participants ineligible for general anesthesia
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
January 1, 2024
Completion date:
December 31, 2025
Lead sponsor:
Agency:
Nicolaus Copernicus University
Agency class:
Other
Source:
Nicolaus Copernicus University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06134024